NeuroSense Therapeutics (NASDAQ:NRSN) Stock Rating Lowered by HC Wainwright

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Monday, Benzinga reports.

A number of other equities research analysts have also weighed in on NRSN. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Wednesday. Roth Capital lowered NeuroSense Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $170.00.

NeuroSense Therapeutics Price Performance

NASDAQ:NRSN traded down $0.71 during mid-day trading on Monday, reaching $1.28. 378,576 shares of the company’s stock traded hands, compared to its average volume of 15,668. The company has a 50 day moving average price of $5.44 and a 200-day moving average price of $12.90. The firm has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.12 and a beta of 1.75. NeuroSense Therapeutics has a 12-month low of $1.10 and a 12-month high of $25.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned approximately 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is aimed at addressing multiple biological mechanisms associated with conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.

Its lead investigational product, PrimeC, is a proprietary oral combination formulation of ciprofloxacin and celecoxib designed to target pathways implicated in ALS, including neuroinflammation and RNA regulation.